GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Frazier Lifesciences Acquisition Corp (NAS:FLAC) » Definitions » EBITDA Margin %

Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) EBITDA Margin % : 0.00% (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Frazier Lifesciences Acquisition EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Frazier Lifesciences Acquisition's EBITDA for the three months ended in Sep. 2022 was $-2.29 Mil. Frazier Lifesciences Acquisition's Revenue for the three months ended in Sep. 2022 was $0.00 Mil. Therefore, Frazier Lifesciences Acquisition's EBITDA margin for the quarter that ended in Sep. 2022 was 0.00%.


Frazier Lifesciences Acquisition EBITDA Margin % Historical Data

The historical data trend for Frazier Lifesciences Acquisition's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frazier Lifesciences Acquisition EBITDA Margin % Chart

Frazier Lifesciences Acquisition Annual Data
Trend Dec20 Dec21
EBITDA Margin %
- -

Frazier Lifesciences Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Frazier Lifesciences Acquisition's EBITDA Margin %

For the Shell Companies subindustry, Frazier Lifesciences Acquisition's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frazier Lifesciences Acquisition's EBITDA Margin % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Frazier Lifesciences Acquisition's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Frazier Lifesciences Acquisition's EBITDA Margin % falls into.



Frazier Lifesciences Acquisition EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Frazier Lifesciences Acquisition's EBITDA Margin % for the fiscal year that ended in Dec. 2021 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-1.366/0
= %

Frazier Lifesciences Acquisition's EBITDA Margin % for the quarter that ended in Sep. 2022 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2022 )/Revenue (Q: Sep. 2022 )
=-2.294/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Frazier Lifesciences Acquisition  (NAS:FLAC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Frazier Lifesciences Acquisition EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Frazier Lifesciences Acquisition's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
601 Union Street, Two Union Square, Suite 3200, Seattle, WA, USA, 9810
Frazier Lifesciences Acquisition Corp is a blank check company.
Executives
David Joseph Topper director, officer: Chief Financial Officer C/O GENERAL ATLANTIC SERVICE COMPANY, LP, 55 EAST 52ND STREET, 32ND FLOOR, NEW YORK NY 10055
Krishna R Polu director C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Robert Jr. Baltera director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830